OnKure Therapeutics Statistics
Share Statistics
OnKure Therapeutics has 13.51M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 13.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 377 |
| FTD / Avg. Volume | 0.77% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.18 and the forward
PE ratio is null.
OnKure Therapeutics's PEG ratio is
-0.04.
| PE Ratio | -2.18 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.1 |
| P/FCF Ratio | -2.24 |
| PEG Ratio | -0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for OnKure Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.73,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.73 |
| Quick Ratio | 10.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -181.29 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,145,065.22 |
| Employee Count | 46 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -89.25% in the
last 52 weeks. The beta is 0.41, so OnKure Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -89.25% |
| 50-Day Moving Average | 3.78 |
| 200-Day Moving Average | 10.53 |
| Relative Strength Index (RSI) | 14.08 |
| Average Volume (20 Days) | 49,280 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -54.39M |
| Net Income | -52.67M |
| EBITDA | -51.71M |
| EBIT | -52.37M |
| Earnings Per Share (EPS) | -3.95 |
Full Income StatementBalance Sheet
The company has 110.76M in cash and 1.08M in
debt, giving a net cash position of 109.68M.
| Cash & Cash Equivalents | 110.76M |
| Total Debt | 1.08M |
| Net Cash | 109.68M |
| Retained Earnings | -154.72M |
| Total Assets | 114.91M |
| Working Capital | 102.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -51.12M
and capital expenditures -52K, giving a free cash flow of -51.17M.
| Operating Cash Flow | -51.12M |
| Capital Expenditures | -52K |
| Free Cash Flow | -51.17M |
| FCF Per Share | -3.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
